The business case
Cell and gene therapies are redefining medicine, but the software tools behind them haven't kept pace. BioPilot provides the purpose-built research engine this industry has been missing.
The core problem
In cell therapy, the product is a living system: variable, time-sensitive, and uniquely complex. Yet researchers still rely on generic tools built for small-molecule chemistry: spreadsheets, disconnected ELNs, and file shares.
The result? Protocol drift, untraceable lineage, irreproducible experiments, and regulatory submissions that collapse under scrutiny. Not because the science failed, but because the records couldn't prove it worked.
A single platform that understands cell therapy workflows natively: experiment design with day-by-day protocols, real-time inventory traceability, integrated FACS and analytics, and structured lineage from cell bank to final product.
Built with GMP-oriented foundations from day one (audit trails, lot tracking, and compliance documentation) at a price point accessible to startups and academic labs, not just large pharma.
Market
The cell and gene therapy sector is industrializing rapidly, but the digital tools supporting it remain fragmented.
Why BioPilot
Unlike generic platforms, BioPilot maps real-world entities (cell lines, media, reagents, vendors, hardware) into a queryable knowledge graph. This eliminates naming chaos and makes cross-experiment comparison reliable.
Built-in FACS gating, image analysis, and scRNA-seq pipelines. Results link directly to experiment records: no exporting, no handoffs, no extra licenses.
Every material, process step, and decision is traced from cell bank to final product. Audit-ready provenance is captured as researchers work, not reconstructed after the fact.
DOE concepts, protocol variations, and optimization boards are native to the workflow. Scientists can rapidly iterate and correlate process parameters with biological outcomes.
Business case
The core thesis: cell therapy needs purpose-built infrastructure, and the sector is large enough, underserved enough, and growing fast enough to support a focused vertical platform.
Irreproducible experiments cost the biomedical sector billions annually. BioPilot's structured data model and enforced ontologies directly reduce variability at its source.
Enterprise platforms cost $50K+/year and require months of configuration. Most cell therapy startups, CDMOs, and academic labs are left with spreadsheets. BioPilot fills this gap.
Deep domain ontology combined with cell-therapy-specific business logic creates natural switching costs. The platform gets more valuable as structured data accumulates across experiments.
Architected for FDA (21 CFR Part 11) and EMA standards from day one. Cloud-native SaaS model with healthy margins. Applicable across regenerative, immuno, and gene therapy workflows.
By reducing failed and irreproducible experiments, BioPilot directly cuts waste of single-use plastics, biological reagents, and energy inherent to cell therapy R&D.
Academic adoption means the next generation of cell therapy researchers trains on BioPilot, creating long-term demand from future industry professionals.